Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low After Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s stock price reached a new 52-week low during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to $1,000.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $618.51 and last traded at $630.08, with a volume of 111538 shares trading hands. The stock had previously closed at $637.36.

Several other brokerages also recently commented on REGN. Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. TD Cowen lowered their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Finally, Bernstein Bank reduced their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $966.88.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in REGN. Willner & Heller LLC lifted its position in shares of Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 15 shares in the last quarter. OLD Second National Bank of Aurora increased its stake in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 15 shares during the last quarter. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the last quarter. TD Private Client Wealth LLC lifted its position in Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 18 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a fifty day moving average price of $682.93 and a two-hundred day moving average price of $791.84. The company has a market cap of $69.34 billion, a P/E ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the company earned $11.86 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.